Background: The goal of the research project Greifswald Approach to Individualized Medicine (GANI_MED) is to implement individualized diagnostic and treatment strategies using clinical routine data from our university hospital. To identify new risk factors and biomarkers of diseases, we are in the process of establishing large patient cohorts for several highly prevalent disease conditions including heart failure, stroke, renal insufficiency, and metabolic syndrome. These patient cohorts will be compared to well characterized samples from a population-based cohort study (the Study of Health in Pomerania; SHIP) in a case-control setting. One important aspect of the GANI_MED project is to use clinically obtained data for research purposes and to ensure adequate standardization and quality of these data. Aim: The aim is to standardize the routine data acquisition in the clinical context and to achieve strict quality control and standardization of these data. Methods: The clinical characterization of the patient cohorts includes standardized questionnaires, basic medical and anthropometric examinations (e.g. blood pressure and somatometric measurements) as well as more complex procedures such as ultrasonographic imaging techniques. We developed several methods to ensure adequate standardization of the data. For the medical history, a standardized interview syntax was programmed and implemented in a mobile data capture software with data
validation function using a tablet PC for medical needs. Data is stored in a data warehouse, and a medical history report is created for clinical use. For all relevant clinical examinations, standard operating procedures (SOPs) were developed which are in line with the standards used within SHIP to ensure best possible comparability between the patient cohorts and the control sample. All physicians and technicians involved in the data acquisition process are trained, certified and supervised regularly. The obtained data are monitored closely, and in certification procedures, inter-and intra-examiner differences-as assessed by Bland-Altman-Plots-must not exceed 5%. For basic medical examinations including e.g. measurement of weight, height and blood pressure, identical devices across all cohorts are used. Regular device certifications, calibrations and comparative studies are performed. Individual feedback to each examiner is provided, and regular meetings with all examiners are organized on a weekly basis to ensure optimal exchange and discussions between examiners and the data quality management. Conclusion: GANI_MED extends current research concepts of individualized medicine by in-depth standardization of clinical routine data. This will be the basis for establishing and validating individualized prevention, diagnostics and treatment strategies in our large patient cohorts. screen for a multitude of parameters requiring only minimal amounts of sample material [1] [2] [3] [4] .
In this presentation the current state of protein microarrays for biomarker discovery, validation and diagnosis will be reviewed together with future demands for their application within the field of personalized medicine. In addition, biomarker discovery activities will be discussed within the context of the FDA's critical path initiative and the European public-private "Innovative Medicines Initiative" (IMI) [5, 6] .
In the last ten years, the area of ELISA, Luminex and multiplex protein chip technology has developed and enthusiastically applied to an enormous variety of biological questions. However, the degree of stringency required in data analysis appears to have been underestimated. As a result, there are numerous published findings that are of questionable quality, requiring further confirmation and/or validation. In the course of feasibility and validation studies a number of key issues in research, development and clinical trial studies must be outlined, including those associated with laboratory design, analytical validation strategies, analytical completeness and data managements. The scope of the following präsentation should provide assistance for defining key parameters in assay evaluation and validation in research and clinical trial projects in prospective medicine. Objectives: Prostate cancer is the most common cancer in men and the prevalence is expected to increase within an ageing society. Screening for elevated serum levels of prostate-specific antigen (PSA) is frequently used for early detection of prostate cancer in healthy men in order to enhance the chance of curative treatment. However, serum PSA has a low cancer specificity resulting in a false positive rate of 70% and more. Reducing the number of unnecessary prostate biopsies triggered by false-elevated PSA serum values would have a highly beneficial effect on both patients and healthcare costs in an ageing population. Methods: Using the proprietary UNIarray ® technology we initiated a study to identify autoantigen markers that distinguish between prostate cancer and healthy men. This panel was further verified employing protein microarray chips. Results: Stratified patient samples were incubated with the currently largest collection of recombinant human proteins available for screening purposes to detect autoantibodies against specific targets. Using plasma samples from 20 prostate cancer (pre-surgery samples, Gleason score of resected prostate: 7-9) and 20 age-matched samples of nondiseased men (PSA: 0.1-0.68 ng/ml) we identified more than 150 prostate cancer candidate autoantigens. These autoantigen proteins were subsequently purified and printed on a protein microarray. For a first verification the protein biochip was used to test plasma or serum samples of 40 prostate cancer patients (Gleason score>7), 40 age-matched men with elevated PSA and negative biopsy (mostly diagnosed as mainly benign hypertrophy & prostatitis) and 40 age-matched control men with normal PSA over several years. Bioinformatic analysis using different methods such as support vector machine (SVM) algorithms, classification trees, neuronal nets and a quantitative threshold method combined with 10-fold cross validation were used to select the most promising candidates for further technical development. A subset of the marker candidates on the biochip prototype already discriminates prostate cancer patients from persons with elevated PSA and biopsy negative with a diagnostic specificity of 73% and a sensitivity of 68%. A multicenter validation study is in progress. Conclusion: Serum autoantibodies are promising biomarker candidates for improvement of specificity of prostate cancer detection. Prostate cancer is the most common cause of lethal cancer in men and the prevalence is expected to increase within an ageing society. Screening for elevated serum levels of prostate-specific antigen (PSA) and/or digital rectal examination (DRE) is frequently used for early detection of prostate cancer. Elevated PSA levels and/or positive DRE result trigger prostate biopsy to confirm cancer in suspect cases. Prostate biopsy is an inconvenient procedure which is associated with surgery-related risks and does not confirm prostate cancer in up to 70 % of cases or more. This leaves patients with an uncertainty about a possible disease and causes further examinations including further biopsies. Reducing the number of unnecessary prostate biopsies would have a highly beneficial effect on both patients and healthcare costs in an ageing population. Consequently, for differentiation between benign prostate disease (mainly benign hypertrophy & prostatitis) and malign prostate cancer, we are developing a protein biochip for a serumbased assay with a novel set of diagnostic markers discovered using the proprietary UNIarray® technology. Briefly, stratified patient samples were incubated with the currently largest collection of recombinant human proteins blotted on PVDF membranes for screening purposes to detect autoantibodies against specific targets. Using plasma samples from 20 prostate cancer and 20 age-matched controls we have identified more than 150 prostate cancer specific candidate autoantigens. All autoantigen candidates detected in patient samples were recombinantly expressed, purified and printed on a protein microarray. For a first verification of these novel markers the protein biochip was used to test 40 plasma samples of prostate cancer patients (Gleason score>7), 40 plasma samples of age-matched persons with elevated PSA and biopsy negative (mostly diagnosed as mainly benign hypertrophy & prostatitis) and 40 plasma samples of age-matched control persons with normal PSA over several years as well as normal DRE. Bioinformatical methods such as support vector machine (SVM) algorithms, classification trees, neuronal nets and a quantitative threshold method combined with 10-fold cross validation are used to select the most promising candidates for further technical development. A subset of the marker candidates on the biochip prototype already discriminates prostate cancer patients from persons with elevated PSA and biopsy negative with a diagnostic specificity of 73% and a sensitivity of 68%.
Conclusion: The UNIarray® technology platform comprises the systematic identification of autoantibody signatures in the serum or plasma of patients. These results may be used for e.g. patient stratification in clinical studies, treatment selection, therapy monitoring, and disease progression testing or diagnostic purposes. A verification study of the prostate cancer marker candidates with>500 samples is ongoing. Rapidly developing and expanding multiplex immunoanalysis opens door for precise and more adequate study of complex processes of physiology and pathophysiology. Cytokines, chemokines and growth factors are excellent candidates for multiplexed analysis because of their complex interrelationships and their complex effect on organism. We have established the assessment of cytokines, angiogenic factors, adhesive molecules, hormones, tumour markers and other biomarkers in various biological materials of human, mouse and rat origin by multiplex immunoanalysis in our laboratory. Clinical application of this method is very wide. xMAP technology is based on binding of studied proteins to the antibodies linked to microspheres with internal spectral code referring to protein identity. The amounts of the bound proteins are determined by a second antibody connected with fluorescent molecule. The measurement is performed on special flow cytometer (luminex instrument), which determines the spectral code of microspheres-the identity of proteins-after an excitation by first laser and after an excitation by second laser it detects the amount of second antibodies on microspheresthe quantity of protein in sample. The concentrations of proteins are assessed according to standard calibration curves assayed with unknown samples. Because of the complex nature of the method, it is important for an investigator to plan precisely the multiplex study before the application. There are three main questions:
1. Which blood sample type is adequate? 2. A number of proteins that is possible to analyse in one well? 3. Is the sensitivity of the method sufficient for all proteins measured?
Currently multiplex is mainly the task for the research field but introduction of this method in clinical use can be expected in the near future, because of its advantages: small sample volume used, complex information on the markers received and potentially low costs at application. However, before the use of multiplex inflammatory biomarkers analyses in clinical practice, the essential step is to standardise the pre-analytical and analytical rules and normal ranges. Support: This study was supported by the research project VZ MSM 0021620819. (i) A strong need to find new sources of innovation in the pharmaceutical industry in order to avoid "pipelines drying up"-softening the "not invented here"-argument (ii) Personalized medicine will gain more importance (iii) Pharmaceutical industry becomes more scienceoriented. In fact, it even becomes more "academic" in structure e.g. establishing "Centers of Excellence" (iv) Academia becomes more "business-like" with an increasing need for third party funding and a redefinition of the "mission of the university".
Knowledge transfer can occur in many different ways. However, this paper will focus on the transfer of technologies. Technology transfer offices (TTOs), which comprehensively were established in most countries not before the turn of the millennium, have demonstrably gained (more) maturity. In particular the life sciences have profited there from. This contribution investigates current trends in technology transfer regarding predictive medicine, focusing on biomarker-licensing. It further outlines different concepts for improvements along this line. Licensing as well as patenting activities have taken off in most industries, including life sciences. Also, biomarkers from all relevant areas of "-omics" are per se patentable, thus fulfilling an important prerequisite for commercialization. Accordingly, the number of respective licensing agreements is swiftly increasing (as of April 28 th Medtrack TM lists 455 agreements relating to biomarkers). Typical agreements relate to biomarker discovery and codevelopment but also to specific biomarkers(−sets). A recent example is the Takeda-Zinfandel agreement covering TOMM40.
Most agreements are concluded between biotech and pharmaceutical companies. However, academic research institutions are a rich source of biomarkers which is reflected in the number of invention reports e.g. at PROvendis. Indeed, several licenses have been signed and there continues to be multitudinous negotiations between academia/TTOs and industry. Several biomarkers which have been identified in academia are now being marketed, including e.g. the multigene-panel of MammaPrint TM . Yet, the path of a biomarker from the academia to industry seems to be particularly winding.
To some degree this is misleading. Biomarkers are relevant for different steps in drug development and application.
Inter alia, biomarkers are essential for studying mode of action of drug candidates. In this case, a detailed validation of a biomarker (by numerous independent scientific studies) will be more important to the industry than a monopoly position. Thus, although no license agreements will be signed, academia contributes enormously to drug development.
To some degree this is due to difficulties of establishing approved diagnostic biomarkers on the market as (often) significant efforts will be necessary convincing physicians and providers of other (allegedly competing) diagnostic tools that there will be a win-win-situation for all stakeholders.
To a large extend, however, reasons can be found within academia. These include the difficulty of conducting/ funding large scale studies with sufficient statistical power according to clinical development standards (however, initiatives, such as the German National Biomarker database, look promising). They also include more general issues of the present technology transfer landscape such as an ongoing need to educate scientists. Background: Three-part differential hematology analyzer, as a common equipment of hematology departments in routine clinical laboratories, is indispensable tool for early diagnostics and monitoring of therapy in different hematological and infectious diseases. Besides regular calibration and quality control according to good laboratory practice, a periodical check of analyzer's reproducibility is essential for getting the high quality results that contribute well to the improvement of the patients care. According to manufacturer's data Medonic CA620 hematology analyzer has the best overall reproducibility of all 3-part differential hematology analyzers currently available on Macedonian market.
Aim of the study: The aim of our study was to determine the reproducibility of hematology analyzer Medonic CA620 after 3 years of intensive exploitation and 90 000 samples analyzed. We have also compared the obtained data with results from similar study conducted after 9 months of intensive exploitation of the same analyzer and with data given from manufacturer. Material and methods: Reproducibility of 3-part differential hematology analyzer Medonic CA620 was assessed by measuring four different fresh samples, each counted 12 times. One of the goals is to contribute with the developed multidisciplinary approaches to the novel strategy in healthcare: predictive, preventive and personalised medicine (PPPM). Core business of PLI consists of R&D activities: cost-effective biosynthetic preparation and characterisation of biologically active molecules of various complexity, from small compounds up to complex biomolecules such as human membrane proteins, in particular drug targets. This includes labelling with stable isotopes ( 13 C, 15 N, 2 H). PLI has unique expertise in biosynthetic preparation of high-valuable molecules from prokaryotes, archea and eukaryotes (algae, yeast, fungus, insect and mammalian cell lines). PLI provides a proprietary technology on "Compositions and methods for stable isotope labelling of biological compounds" (PCT/NL03/00514). In November 2010 the patent is granted in Australia, AU 2004256368, and in January 2011 in Russian Federation, RU 2409657 C2. The patent application is pending in Europe, USA, Canada and Japan. PLI is offering license on the technology platform related with stable isotope ( 13 C, 15 N, 2 H) labelling.
As an example, preparation of stable-isotope labelled drug targethuman histamine H1 receptor for ssNMR structural analysis will be shown. Labelling with stable isotopes in mammalian and insect cell lines opens prospects for the preparation of high-valuable biomolecules for various applications: metabolomics, proteomics, structural biology, PPPM. Novel approaches on FT-IR rapid assessment to new sources of specific biomolecules and to the level of stable isotope enrichment will be demonstrated. In addition, rapid assessment to the level of unsaturation of fatty acids will be demonstrated. The technologies have a potential value to accelerate drug discovery and drug design and to develop new products for predictive diagnostics. The PLI's technology platform opens new prospects for both, cost-effective labelling of biologically active molecules and fast non-invasive analysis, which is crucial for the development of new PPPM strategies.
Implementations and future outlook include:
& Quantification of novel diagnostics biomarkers in various branches of medicine and disease areas such as cancer, cardiovascular, diabetes, allergic, neurodegenerative diseases and other; & Non-invasive fast screening of new sources of bioingredients and health-promoting biomolecules to be applied in functional foods and personalized therapies;
& Structure-functional insights in interactions of healthpromoting biomolecules and/or drugs with the drug targets with the aim to prevent pathologies and develop individualised strategies.
